• Wondering if PTC Therapeutics at around US$66.13 is giving you a fair deal or asking too much for its future potential? This article breaks down what the current price might be implying.
• The stock has seen a mixed run recently, with a 1.3% gain over the last 7 days, a 2.4% decline over 30 days, a 13.8% decline year to date, a 21.9% return over 1 year, and 36.5% and 34.4% over 3 and 5 years respectively.
• Recent attention on PTC Therapeutics has centered on how investors are reassessing the company within the wider pharmaceuticals and biotech space, especially as sentiment around the sector evolves over multi year periods. This context helps explain why shorter term moves can look different from the longer term return profile shown in the data above.
• Right now, PTC Therapeutics has a valuation score of 5 out of 6. The next sections will unpack what different valuation methods say about that score, with an even more useful way to think about value saved for the end.

Approach 1: PTC Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting them back to a single present value figure.

For PTC Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. It starts from the latest twelve month free cash flow of about $464.7 million and then applies analyst estimates out to 2030, with Simply Wall St extrapolating beyond the explicit forecasts. For example, projected free cash flow for 2030 is $484 million, and the model continues to extend those projections through to 2035 using estimated growth rates.

When all those future cash flows are discounted back, the DCF model suggests an estimated intrinsic value of about $176.54 per share. Compared with the recent share price of about $66.13, this output implies the stock is 62.5% undervalued according to this specific model and its assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests PTC Therapeutics is undervalued by 62.5%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: PTC Therapeutics Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you pay for a share to the earnings that company is currently generating. It effectively tells you how many years of current earnings the market is pricing into the stock.

What counts as a “normal” P/E often reflects how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk tends to align with a lower P/E.

PTC Therapeutics trades on a P/E of about 8x. That sits below both the Biotechs industry average of around 15.1x and a peer group average of about 26.6x. Simply Wall St’s Fair Ratio, which is 14.7x, goes a step further. It is a proprietary estimate of what P/E might be appropriate after considering factors such as earnings growth, profit margins, industry, market cap and specific company risks.

Because the Fair Ratio adjusts for these elements, it can be more informative than a simple comparison with peers or the broad industry. With the current P/E of 8x sitting below the 14.7x Fair Ratio, the stock screens as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your PTC Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives step in as short, clear stories that link your view of PTC Therapeutics to a set of numbers by tying together your assumptions for future revenue, earnings and margins. This turns those assumptions into a Fair Value which you can compare with the current price to help decide whether to wait, buy or sell, all within Simply Wall St’s Community page where Narratives are available to millions of investors and are updated automatically when new news or earnings arrive. For PTC Therapeutics, one investor might lean toward a higher Fair Value around US$121.11, based on expectations for earnings of US$694.2m by about March 2029 and a P/E of 20.7x. Another might anchor on a lower Fair Value near US$44.00, tied to assumptions of earnings of US$136.6m by about September 2028 and a P/E of 34.5x. Narratives make those different views transparent so you can quickly see which story and set of forecasts fits your own outlook.

For PTC Therapeutics however we will make it really easy for you with previews of two leading PTC Therapeutics Narratives:

Both are built from the same underlying analyst data but they lean in very different directions, which helps you benchmark your own view against what other investors are focusing on.

Fair value in this bullish narrative: US$121.11 per share

Implied undervaluation versus the recent US$66.13 share price: about 45%

Revenue growth assumption: 3.09% a year

• Sephience and the Huntington’s collaboration are treated as the main engines for future earnings, supported by global expansion across rare disease franchises.
• The rare disease portfolio and existing commercial footprint are expected to support ongoing cash generation, with optionality for business development and pipeline expansion.
• To line up with this view, you would need to be comfortable with earnings of about US$694.2m by around 2029 and a future P/E of roughly 20.7x on those earnings.

Fair value in this bearish narrative: US$55.00 per share

Implied overvaluation versus the recent US$66.13 share price: about 20%

Revenue growth assumption: 19.60% annual contraction

• This view places more weight on pressure from healthcare cost controls, tougher regulatory review and competition, which are all seen as headwinds for new therapies like Sephience.
• Reliance on a relatively narrow product set and ongoing cash burn are framed as key risks that could lead to future dilution and limit upside in earnings per share.
• To agree with this case, you would need to assume revenues of about US$840.8m and earnings of roughly US$136.6m by 2028, with the market still paying around 34.5x earnings at that point.

Do you think there's more to the story for PTC Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.